UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

July 2, 2021 (Date of earliest event reported)

LABORATORY CORPORATION OF AMERICA HOLDINGS

		(Exact N	ame of Registrant as Specified i	n its Charter)		
Delaware			1-11353		13-3757370	
(State or other jurisdiction of Incorporation)			(Commission File Numb	er) (I.R	.S. Employer Identification No.)	
	358 South I					
Burling		North Car	rolina	27215 (Zip Code)		
(A)	address of principa	al executive offices)		(Zīp	Code)	
		(Registrant's te	lephone number including area o	code) 336-229-1127		
Check the appropriate following provisions		the Form 8-K filing	is intended to simultaneously s	satisfy the filing obliga	ation of the registrant under any of the	
□ Soliciting mate□ Pre-commence	Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))					
Securities registered	pursuant to Section	on 12(b) of the Excha	nge Act.			
Title of Each Class Common Stock , \$0.	Trading S 10 par value		of exchange on which registered rk Stock Exchange	d		
	-2 of the Securitie		g growth company as defined in 134 (§240.12b-2 of this chapter).		ties Act of 1933 (§230.405 of this	
	th company, indic	ate by check mark if t	the registrant has elected not to u to Section 13(a) of the Exchang		on period for complying with any new	
Item 7.01	Regulation FD I	Disclosure				
Thursday, July 29, 29 and accompanying fi	021. The companimancial information	y will host a conference on will be posted on t		at 9 a.m. ET that day to	rter of 2021 before the market opens on discuss the results. The earnings release	
Item 9.01	Financial State	ments and Exhibits.				
Exhibit Exhibit 99.1	Exhibit Name Press release dat	<u>ed July 2, 2021 issued</u>	<u>d by Labcorp</u>			

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

LABORATORY CORPORATION OF AMERICA HOLDINGS

Registrant

By: /s/ SANDRA VAN DER VAART

Sandra van der Vaart Executive Vice President, Chief Legal Officer and Corporate Secretary

July 2, 2021



FOR IMMEDIATE RELEASE

Labcorp Contacts:

Investors: Chas Cook — 336-436-5076

Investor@Labcorp.com

Media: Chris Allman-Bradshaw – 336-436-8263

Media@Labcorp.com

LABCORP TO ANNOUNCE SECOND QUARTER FINANCIAL RESULTS ON JULY 29, 2021

BURLINGTON, N.C., July 2, 2021 — Labcorp (NYSE: LH), a leading global life sciences company, will release its financial results for the second quarter of 2021 before the market opens on Thursday, July 29, 2021. The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings release and accompanying financial information will be posted on the Labcorp Investor Relations website.

Interested parties can access the conference call by dialing 1-877-898-8036 within the U.S. and Canada, or 1-720-634-2811 internationally, using the conference ID 1789612. In addition, a real-time webcast of the conference call will be available on the Labcorp Investor Relations website.

An audio replay of the conference call will be available from 1 p.m. ET on July 29, 2021, until 11:30 p.m. ET on August 12, 2021, by dialing 1-855-859-2056 within the U.S. and Canada, or 1-404-537-3406 internationally, using the conference ID 1789612. The webcast of the conference call will be archived and accessible through July 15, 2022, on the <u>Labcorp Investor Relations website</u>.

About Labcorp

Labcorp is a leading global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. Through our unparalleled diagnostics and drug development capabilities, we provide insights and accelerate innovations to improve health and save lives. With more than 70,000 employees, we serve clients in more than 100 countries. Labcorp (NYSE: LH) reported revenue of \$14.0 billion in FY2020. Learn more about us at www.Labcorp.com or follow us on LinkedIn and Twitter @Labcorp.

###